<SEC-DOCUMENT>0001144204-17-025336.txt : 20170508
<SEC-HEADER>0001144204-17-025336.hdr.sgml : 20170508
<ACCEPTANCE-DATETIME>20170508172824
ACCESSION NUMBER:		0001144204-17-025336
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170504
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170508
DATE AS OF CHANGE:		20170508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		17823576

	BUSINESS ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		804-827-2524

	MAIL ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v466410_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report (Date of earliest event
reported): May 4, 2017 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-37544 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AmpliPhi
Biosciences Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Washington</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1549568</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction of incorporation or</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>organization)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3579 Valley Centre Drive, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California 92130</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(858) 829-0829</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s Telephone number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect; 240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings">&yacute;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&yacute;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 4, 2017, we entered into an underwriting
agreement with H.C. Wainwright &amp; Co., LLC, relating to the issuance and sale of 6,956,522 shares of our common stock (or pre-funded
warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 6,956,522 shares of our
common stock in an underwritten public offering. Each share of common stock and, as applicable, pre-funded warrant is being sold
together with a common warrant to purchase one share of common stock. The combined price to the public of each share of common
stock and accompanying common warrant will be $1.50, and $1.49 for each pre-funded warrant and accompanying common warrant. For
each pre-funded warrant we sell, the number of shares of common stock we sell and issue at the closing of the offering will be
decreased on a one-for-one basis. The common warrants will be immediately exercisable at a price of $1.50 per share of common stock,
subject to adjustment in certain circumstances, and will expire five years from the date of issuance. The shares of common stock
and pre-funded warrants, and the accompanying common warrants, will be issued separately and will be immediately separable upon
issuance. The offering is expected to close on or about&nbsp;May 10, 2017, subject to customary closing conditions.&nbsp; We issued
a press release announcing the pricing of the offering on May 4, 2017, which is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We granted to the underwriter a 30-day
option to purchase up to an additional 1,043,478 shares of common stock and/or warrants to purchase up to 1,043,478 shares of our
common stock, at the public offering price less discounts and commissions. The option to purchase 1,043,478 shares of our common
stock and accompanying warrants to purchase 1,043,478 shares of our common stock has been exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds to&nbsp;us&nbsp;from the
offering are expected to be approximately $10.4 million (including the net proceeds from the exercise of the option to purchase
additional shares of common stock and accompanying common warrants), after deducting the underwriting discount and commissions
and estimated offering expenses payable by&nbsp;us, and excluding any proceeds that may be received upon exercise of the common
warrants. We anticipate using the net proceeds from the offering for general corporate purposes, including manufacturing expenses,
clinical trial expenses, research and development expenses, general and administrative expenses and certain contractual bonuses
to our executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A registration statement relating to these
securities (File No. 333-217169) was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on May 4,
2017.&nbsp;&nbsp;In addition, a separate registration statement relating to these securities (File No. 333-217680) was filed with
the SEC pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and become automatically effective on May 4, 2017. <FONT STYLE="background-color: white">The
offering is being made only by means of a prospectus forming a part of the effective registration statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the pre-funded
warrants and common warrants is not complete and is qualified in its entirety by reference to the full text of the form of pre-funded
warrant and form of common warrant, copies of which are filed as Exhibit 4.1 and Exhibit 4.2, respectively, to this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
disclosures in this report and in the attached press release shall not constitute an offer to sell or a solicitation of an offer
to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.&nbsp;</B></FONT></TD>
    <TD STYLE="width: 90%; border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.19 to the registrant&rsquo;s registration statement on Form S-1 (File No. 333-217169)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Form of Common Warrant (incorporated by reference to Exhibit 4.18 to the registrant&rsquo;s registration statement on Form S-1 (File No. 333-217169)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Press Release</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #61116A"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #61116A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Statements in this report that are
not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include, without limitation, statements about our expectations regarding the completion,
timing and size of the public offering and the anticipated use of net proceeds therefrom. Words such as &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;goal,&rdquo; &ldquo;potential&rdquo; and similar expressions are intended to identify forward-looking statements, though
not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results
to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated
with&nbsp;our business and financial condition in general, including the risks and uncertainties described in our Annual Report
on Form 10-K for the year ended December 31, 2016, as filed with the SEC, and subsequent filings with the SEC. You are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. All forward-looking
statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update any
forward-looking statements to reflect events or circumstances after the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: May 8, 2017</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>AmpliPhi Biosciences Corporation</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Steve R. Martin</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Steve R. Martin</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.&nbsp;</B></FONT></TD>
    <TD STYLE="width: 90%; border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.19 to the registrant&rsquo;s registration statement on Form S-1 (File No. 333-217169)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Form of Common Warrant (incorporated by reference to Exhibit 4.18 to the registrant&rsquo;s registration statement on Form S-1 (File No. 333-217169)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Press Release</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v466410_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; font-size: 10pt; text-indent: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0; text-align: right">AmpliPhi Biosciences Corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0; text-align: right">3579 Valley Centre Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0; text-align: right">San Diego, CA 92130</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7030A0">&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AmpliPhi Biosciences Announces Pricing
of $10.4 Million Underwritten Public Offering of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock and Common Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>San
Diego (</B></FONT><B>May 4, 2017) &ndash;</B> AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused
on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing
of an underwritten public offering of 6,956,522 shares of its common stock (or pre-funded warrants to purchase common stock in
lieu thereof), and common warrants to purchase up to an aggregate of 6,956,522 shares of common stock. Each share of common stock
and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a
combined effective price to the public of $1.50 per share and accompanying common warrant. For each pre-funded warrant AmpliPhi
sells, the number of shares of common stock AmpliPhi is offering will be decreased on a one-for-one basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The common warrants will be immediately
exercisable at a price of $1.50 per share of common stock and will expire five years from the date of issuance. The shares of common
stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will
be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about<FONT STYLE="color: #16211F">&nbsp;</FONT>May
10, 2017, subject to customary closing conditions.<FONT STYLE="color: #16211F">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rodman &amp; Renshaw, a unit of H.C. Wainwright
&amp; Co., is acting as the sole book-running manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AmpliPhi also has granted to the underwriter
a 30-day option to purchase up to an additional 1,043,478 shares of common stock and/or warrants to purchase up to 1,043,478 shares
of common stock of AmpliPhi, at the public offering price less discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds to<FONT STYLE="color: #16211F">&nbsp;</FONT>AmpliPhi<FONT STYLE="color: #16211F">&nbsp;</FONT>from
this offering are expected to be approximately<FONT STYLE="color: #16211F">&nbsp;</FONT>$9.8 million, after deducting underwriting
discounts and commissions and before deducting other offering expenses payable by<FONT STYLE="color: #16211F">&nbsp;</FONT>AmpliPhi,
and excluding any proceeds that may be received upon exercise of the warrants. AmpliPhi<FONT STYLE="color: #16211F">&nbsp;</FONT>anticipates
using the net proceeds from the offering for general corporate purposes, including manufacturing expenses, clinical trial expenses,
research and development expenses and general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A registration statement relating to these
securities was declared effective by the Securities and Exchange Commission (SEC) on May 4, 2017.&nbsp; The offering is being made
only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus relating to
the offering, when available, may be obtained for free by visiting the<FONT STYLE="color: #16211F">&nbsp;</FONT>SEC&rsquo;s<FONT STYLE="color: #16211F">&nbsp;</FONT>website
at<FONT STYLE="color: #16211F">&nbsp;</FONT>http://www.sec.gov, or alternatively from the offices of H.C. Wainwright &amp; Co.,
LLC by email at placements@hcwco.com or by phone at 646-975-6996.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute
an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About AmpliPhi Biosciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AmpliPhi Biosciences Corporation is a biotechnology
company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based
technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage
therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two
Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary
efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Bacteriophage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bacteriophages, or more simply &ldquo;phages,&rdquo;
are the natural predators of bacteria and are thought to be the most abundant life form on earth. Over eons, phages have evolved
an incredible diversity of specialist strains that typically prey upon just one strain of bacteria, enabling phage therapies to
precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they
are antibiotic-resistant or not, and even when they have formed protective biofilms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statements in this press release that are
not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include, without limitation, statements about AmpliPhi&rsquo;s expectations regarding
the completion, timing and size of the public offering and the anticipated use of net proceeds therefrom. Words such as &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo;
&ldquo;goal,&rdquo; &ldquo;potential&rdquo; and similar expressions are intended to identify forward-looking statements, though
not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results
to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated
with&nbsp;AmpliPhi&rsquo;s business and financial condition in general, including the risks and uncertainties described in AmpliPhi&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC, and other filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation
to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matthew Dansey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AmpliPhi Biosciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(858) 800-4869</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">md@ampliphibio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jody Cain</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LHA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(310) 691-7100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jcain@lhai.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -P# 2(  A$! Q$!_\0
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MU";2?#.IZA;!#/;6LDL>\9&Y5)&17D5C\2_B!<Z/+KD6DV5SID#E9I%B/RX
M)R ^1P1SC%>I^-_^1%UW_KQF_P#0#7AWA/QA?Z?X'O\ PYINB7%[<WLD@$R
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MI()_+E1D=3@JPP17'_$O_DH&I_2'_P!%)7TIJNA6&L1XN81Y@^[*O#+^/?\
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MU.]M$N95FN;6(H8IG&!GYE)&0 #@C-;U%',PYF<O>>![.ZLY;<7ES$9-3;5
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>;FW6>4RF*,KL0G&0N1P.,X]Z[:BGSR[CYY+J?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
